09:00pm Monday 11 December 2017

Protein injection points to muscular dystrophy treatment

These results were published today in the Proceedings of the National Academy of Sciences by Dr. Julia von Maltzahn and Dr. Michael Rudnicki, the Ottawa scientist who discovered muscle stem cells in adults.

“This is an unprecedentedand dramatic restoration in muscle strength,” says Rudnicki, a senior scientist and director for the Regenerative Medicine Program and Sprott Centre for Stem Cell Research at the Ottawa Hospital Research Institute. He is also Canada Research Chair in Molecular Genetics and a professor in the Faculty of Medicine at the University of Ottawa.

“We know from our previous work that this protein, called Wnt7a, promotes the growth and repair of healthy muscle tissue. In this study we show the same types of improvement in a mouse model of Duchenne muscular dystrophy. We found that Wnt7a injections increased muscle strength almost two-fold, to nearly normal levels. We also found that the size of the muscle fibre increased, and there was less muscle damage compared to mice not given Wnt7a.”

Duchenne muscular dystrophy is a genetic disorder that affects one of every 3,500 newborn males. In Canada, all types of muscular dystrophy affect more than 50,000 people. The disease often progresses to a state where the muscles are so depleted that the person dies due to an inability to breath. For people with Duchenne muscular dystrophy, this usually happens in their 20s or 30s.

The researchers are developing Wnt7a as a biological therapeutic for this devastating disease, in collaboration with biotechnology company Fate Therapeutics. They hope to start clinical trials for Duchenne muscular dystrophy treatment in the near future. “This is also exciting, because we think it’s a therapeutic approach that could apply to other muscle-wasting diseases,” says Rudnicki.

Rudnicki’s lab is a world leader in research on muscle stem cells. It has contributed significantly to our understanding of how these cells work at the molecular level. This research takes place in OHRI’s multidisciplinary environment of collaboration with clinicians, and has led to the identification of Wnt7a as a promising candidate to help people with muscle wasting disease.

The full article, Wnt7a treatment ameliorates muscular dystrophy is available ahead of publication in print on the Proceedings of the National Academy of Sciences website.

This research was supported by the Muscular Dystrophy Association, the Ontario Ministry of Economic Development and Innovation, the Canadian Institutes of Health Research, the National Institutes of Health, the Howard Hughes Medical Institute, and the Canada Research Chair Program. All research at OHRI is also supported by the Ottawa Hospital Foundation.

-30-

INFORMATION:

Néomie Duval
Media Relations Officer
University of Ottawa
Office: 613-562-5800 ext. 2981
Cell: 613-863-7221
neomie.duval@uOttawa.ca

Paddy Moore
Manager, Communications and Public Relations,
Ottawa Hospital Research Institute
613-798-5555 ext. 73687
613-794-6912 (cell)
padmoore@ohri.ca


Share on:
or:

MORE FROM Bones and Muscles

Health news